Viatris Inc. (VTRS) Stock Profile & Financial OverviewViatris Inc.
VTRS Company Overview & Business Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Key Information
Current Trend for VTRS
An assessment of the current trend environment for VTRS, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for VTRS is a Strong Momentum Environment (High Conviction Uptrend).
Daily and weekly trends are in bullish alignment, forming a strong medium-term uptrend.
- The weekly backdrop provides strong tailwinds, confirming that the medium-term path of least resistance is upward.
- Price is currently trending at a healthy distance, sitting 1.62 ATR away from the adaptive KAMA baseline.
- Technical Update: Price has breached a key Fractal High, confirming a structural breakout to the upside.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, VTRS in a strong expansion phase; Long-term trend is bullish.
Trend Strength: VTRS last closed at 12.24, trading 1.1 ATR above the adaptive KAMA baseline (11.90). Technical Classification: Confirmed High-Momentum Uptrend.
Trend Score: Technical Score: 95/100. Classification: Strong/Established. Alignment: High. Logic: Full multi-timeframe alignment with strong momentum filters.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 10.50. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Constructive Upside. Daily and weekly trends are in high-quality alignment with healthy momentum. Risk skew favors continued upside follow-through from current levels.
Key Levels: In this bullish structure, key support is anchored by immediate support (KAMA) at 11.90, with the critical trend-guard (SuperTrend) at 10.50.